Business

Biote Formalizes Commitment to Men’s Hormone Health With Launch of New Men’s Health Division

Leader in Hormone Education and Training Aims to Increase Awareness and Access to Testosterone Deficiency Therapy through Expanded Network of Urologists and

articleBiote Corp.June 22, 20233/company/biote-corp/news/biote-formalizes-commitment-to-mens-hormone-health-with-launch-of-new-mens-health-division
Biote Formalizes Commitment to Men’s Hormone Health With Launch of New Men’s Health Division

About this update from Biote Corp.

[{"type":"text","content":"\nLeader in Hormone Education and Training Aims to Increase Awareness and Access to Testosterone Deficiency Therapy through Expanded Network of Urologists and Internal Medicine Practitioners\n\n\n IRVING, Texas--(BUSINESS WIRE)--\nbiote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, has announced the launch of a new Men’s Health Division with the mission of redefining wellness for men through innovation in hormone education and optimization. Coinciding with National Men’s Health Month and headed by Biote General Manager John Denne, this new division will focus on increasing awareness, education and access to treatment for the estimated 39% of men over the age of 45 who are affected by testosterone deficiency in the United States.\n\n\n“Men tend to think about health as the absence of disease and are reluctant to ask their healthcare provider about symptoms of low testosterone such as poor sleep, low sex drive, anxiety and depression, and low energy,” explains Terry Weber, CEO of Biote. “Establishing a division dedicated specifically to men was a logical step in our commitment to increase the number of providers in our network who are educated and trained to meet the specific needs and preferences of male patients.”\n\n\nLow testosterone, also called hypogonadism, can be detected with a blood test and is diagnosed when a person has low testosterone levels while also experiencing symptoms. In general, men experience a 44% reduction of testosterone between ages 30 and 74 at the rate of roughly 1 percent each year, unlike women who experience a sudden drop in hormone levels at menopause. However, despite access to care, only 12% of clinically symptomatic men are successfully treated for low testosterone.\n\n\n“When you ask a man about his cholesterol or blood pressure level he will usually know if he is in a healthy range, but if you ask about his hormone levels, he will likely have no idea,” says Marc Beer, Executive Chairman of Biote. “This new division will focus on educating and motivating men to recognize and seek treatment for symptoms of low testosterone. At the same time, we are providing the necessary tools and resources for urologists and internal medicine practitioners to effectively treat these male patients who come through the door looking for solutions.”\n\n\nRoger Dmochow...

More updates from Biote Corp.